Alterations in human circulating and bone marrow mononuclear cell polyamine levels in hematologic malignancies as a consequence of difluoromethylornithine administration.
The effect of administering increasing intravenous doses of difluoromethylornithine on human tumor cell polyamine levels was determined in patients with hematologic malignancies. Difluoromethylornithine from 5.5. to 64 gm/m2 per day was administered to nine patients with refractory acute leukemia or multiple myeloma. Putrescine, spermidine, and spermine levels were determined on a daily basis in the circulating mononuclear cells and on a weekly basis in the mononuclear cells of the bone marrow. Tumor cell putrescine levels declined in 5 patients, spermidine levels declined in 4 patients, and spermine levels declined in 3 patients. Alterations in the polyamine levels of the bone marrow mononuclear cells paralleled those occurring in the peripheral blood mononuclear cells in the patients with leukemia. Seven to ten days of DFMO treatment were required for mononuclear cell polyamine levels to decrease. The higher drug doses were not significantly more effective than the lower doses in bringing about a decline in tumor cell polyamine levels, either with respect to treatment time required for onset of response or with respect to the ultimate extent of response.
D000293:Adolescent; D000328:Adult; D000368:Aged; D015317:Biogenic Polyamines / Q000097:blood*; D001853:Bone Marrow / Q000032:analysis*; D000518:Eflornithine / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007938:Leukemia / Q000097:blood*; D007963:Leukocytes, Mononuclear / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood
D015317:Biogenic Polyamines; D000518:Eflornithine